Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug528 | BMS-986337 Placebo Wiki | 0.50 |
| drug536 | BRII-198 Wiki | 0.50 |
| drug3810 | SELF-BREATHE Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3983 | Single Session Problem-Solving Intervention Wiki | 0.50 |
| drug527 | BMS-986337 Wiki | 0.50 |
| drug550 | Bamlanivimab Wiki | 0.50 |
| drug909 | Cannabis, Medical Wiki | 0.50 |
| drug3218 | Placebo Comparator Wiki | 0.35 |
| drug541 | Bacille Calmette-Guérin (BCG) Wiki | 0.35 |
| drug1640 | Famotidine Wiki | 0.22 |
| drug3195 | Placebo Wiki | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000070627 | Chronic Traumatic Encephalopathy NIH | 0.50 |
| D005879 | Tourette Syndrome NIH | 0.50 |
| D017093 | Liver Failure NIH | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001714 | Bipolar Disorder NIH | 0.35 |
| D012640 | Seizures NIH | 0.29 |
| D006526 | Hepatitis C NIH | 0.29 |
| D000690 | Amyotrophic Lateral Sclerosis NIH | 0.25 |
| D016472 | Motor Neuron Disease NIH | 0.25 |
| D005356 | Fibromyalgia NIH | 0.22 |
| D001927 | Brain Diseases NIH | 0.20 |
| D001987 | Bronchiectasis NIH | 0.20 |
| D000070642 | Brain Injuries, Traumatic NIH | 0.17 |
| D015212 | Inflammatory Bowel Diseases NIH | 0.17 |
| D003550 | Cystic Fibrosis NIH | 0.17 |
| D004417 | Dyspnea NIH | 0.15 |
| D010300 | Parkinsonian NIH | 0.15 |
| D001930 | Brain Injuries, NIH | 0.14 |
| D059350 | Chronic Pain NIH | 0.13 |
| D017563 | Lung Diseases, Interstitial NIH | 0.13 |
| D003424 | Crohn Disease NIH | 0.13 |
| D009103 | Multiple Sclerosis NIH | 0.11 |
| D012598 | Scoliosi NIH | 0.11 |
| D008171 | Lung Diseases, NIH | 0.09 |
| D040921 | Stress Disorders, Traumatic NIH | 0.09 |
| D014947 | Wounds and Injuries NIH | 0.08 |
| D013313 | Stress Disorders, Post-Traumatic NIH | 0.08 |
| D004194 | Disease NIH | 0.08 |
| D013577 | Syndrome NIH | 0.04 |
| D003141 | Communicable Diseases NIH | 0.03 |
| D007239 | Infection NIH | 0.02 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
| D018352 | Coronavirus Infections NIH | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001399 | Hepatic failure HPO | 0.50 |
| HP:0100754 | Mania HPO | 0.35 |
| HP:0006802 | Abnormal anterior horn cell morphology HPO | 0.25 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0007354 | Amyotrophic lateral sclerosis HPO | 0.25 |
| HP:0001250 | Seizure HPO | 0.22 |
| HP:0001298 | Encephalopathy HPO | 0.20 |
| HP:0002110 | Bronchiectasis HPO | 0.20 |
| HP:0002037 | Inflammation of the large intestine HPO | 0.17 |
| HP:0002098 | Respiratory distress HPO | 0.15 |
| HP:0012532 | Chronic pain HPO | 0.13 |
| HP:0006515 | Interstitial pneumonitis HPO | 0.13 |
| HP:0100280 | Crohn's disease HPO | 0.13 |
| HP:0002088 | Abnormal lung morphology HPO | 0.09 |
Navigate: Correlations HPO
There are 4 clinical trials
This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
Description: Covid-19 infection rates in cannabis users will be compared to rates in the general population. Our online questionnaire responses will compare infection rates of cannabis users in this study against the Johns Hopkins University Coronavirus Research Center data (https://coronavirus.jhu.edu).
Measure: Prevention of COVID-19 Time: Five yearsDescription: Severity of persistent symptoms in cannabis users testing positive for active infection and/or antibodies will also be compared to the general population. Patients will answer the widely used FLU-PRO questionnaire, which asks about flu symptoms and severity, to capture diagnoses, symptoms, and medical interventions related to COVID-19. The data from cannabis user patients will be compared with national and international data surveys, such as the Covid Symptom Study (https://covid.joinzoe.com/us-2).
Measure: Treatment of COVID-19 Time: Five yearsDescription: The primary objective is to assess the efficacy and safety of medical cannabis as medicine for treatment of chronic pain and other chronic debilitating diseases. Pain will be measured by Brief Pain Inventory (BPI) numeric scale. Change from baseline in BPI will be assessed at 3-month intervals. For prospective associations between cannabis use and outcomes, use of a lagged mixed-effects models will examine temporal associations between cannabis use and pain severity, opioid sparing, and patient satisfaction. Data will be analyzed from baseline and the annual follow-up waves.
Measure: Treatment of Symptoms Time: Five yearsDescription: Secondary objectives include evaluating increases or decreases in quality of life, and increases or decreases in concomitant opioid use. Satisfaction with treatment will be measured by a Visual Analog Score (VAS). Change From baseline in Satisfaction with treatment measured by (VAS) be assessed at 3-month intervals.
Measure: Cannabis Impact on Quality of Life Time: Five yearsDescription: Tertiary objectives will examine preferences for routes of administration, and preferences for THC / CBD ratios. Categorical factors will be summarized using frequencies and percentages, while continuous measure distributions will be described using means, standard deviations, and quartiles of interest.
Measure: Cannabis Route and Dosing Time: Five yearsDescription: Incidence of Treatment-Related Adverse Events will be measured by Physician Global Assessment (PGA) numeric scale. Number of participants with Treatment-Related Adverse Events will be assessed by CTCAE v4.0.
Measure: Monitoring Adverse Events Time: Five yearsBackground: Sickle cell disease (SCD) is a chronic illness. It affects about 100,000 people in the United States. People with SCD have red blood cells that are sickle-shaped and impaired in their function. This results in a lifetime of complications that affect every organ system. People with SCD also are at greater risk for respiratory infections and lung problems. Researchers want to study how this population s stress, anxiety, fear, pain, sleep, and health care use are being affected by the COVID-19 pandemic. Objective: To study the extent and impact of life changes induced by the COVID-19 pandemic on people living with SCD in the U.S. Eligibility: People age 18 and older with SCD who live in the U.S. Design: Participants will complete a survey online. The questions will focus on the following: Medical history Mental and physical health Demographics Stress Resilience Health care use COVID-19 Beliefs about medical mistrust and participation in research. At the end of the survey, participants will be asked if they would like to take the survey again in the future. If they reply yes, then they will be contacted by the study team in 6 months to take the survey again. They may complete the survey again in 6 months, 12 months, and 18 months. The survey should take less than 40 minutes to complete. Participants data will be coded to protect their privacy. The coded data may be shared with other researchers.
Description: We will examine how theo COVID-19 pandemic impacts stress levels among individuals with sickle cell disease (SCD).
Measure: Stress Time: baseline, month 6, month 12, month 18Description: We will examine how the COVID-19 pandemic impacts anxiety levels among individuals with SCD.
Measure: Anxiety Time: baseline, month 6, month 12, month 18Description: This is an examination of questions relating to depression, which we will examine within our cohort.
Measure: Depressive symptomology Time: baseline, month 6, month 12, month 18Description: We will examine the association between clinical severity of SCD and an individual s response to the COVID-19 pandemic.
Measure: Pain episodes, and severity Time: baseline, month 6, month 12, month 18Description: We will investigate the impact of the COVID-19 pandemic on healthcare utilization for SCD individuals.
Measure: Healthcare utilization (primary care, emergency department, telehealth other) Time: baseline, month 6, month 12, month 18Description: We would like to explore how the attitudes about treatment and levels of trust will serve as mediating factors for the experiences of individuals with SCD during this pandemic.
Measure: Receptivity to future health recommendations and medical treatment(s). Time: baseline, month 6, month 12, month 18A feasibility RCT comprising two groups: 1. Intervention (SELF-BREATHE in addition to standard NHS care) 2. Control group (standard / currently available NHS care)
Description: The number of patients recruited into this study over a 12-month period
Measure: Feasibility: the number of patients recruited into this study over a 12-month period Time: 12 monthsThis study seeks to utilize an innovative approach of a single session problem-solving intervention to address psychosocial factors affecting patient outcomes within the pediatric sickle cell population. The study will be a randomized control trial of a single session problem-solving intervention. This original research will investigate the feasibility and efficacy of utilizing a single-session problem-solving intervention to address problems affecting children and families receiving chronic blood transfusions for sickle cell disease in order to: 1) contribute to literature related to single session problem solving interventions with the chronic transfusion sickle cell population and 2) identify a model of sustainable care that reduces the burden of a multiple session intervention and increases access to services. Additionally, this research aims to provide relatively low burden and potentially highly effective intervention into regular care for this population in order to evaluate the feasibility of integrating a single-session problem solving intervention into routine clinical flow, thereby addressing needs more systematically that have been identified by families. Further, this research aims to identify potential utility of medical providers being trained on providing the intervention, which could be part of a future study.
Description: Feasibility of utilizing the intervention will be measured by counting the number of participants who meet the eligibility criteria and enroll in the study
Measure: Feasibility of utilizing the intervention as measured by the number of participants who are eligible and enroll in the study Time: Time of enrollment, approx. 2-3 days from initial recruitment attemptDescription: Feasibility of utilizing the intervention as measured by counting the number of participants who enrolled and were retained through Visit 4.
Measure: Feasibility of utilizing the intervention as measured by the number of participants who enrolled and were retained through Visit 4. Time: Time of enrollment until completion of study, approx. 12 monthsDescription: Acceptability will be measured by the AARP (Abbreviated Acceptability Rating Profile) questionnaire. AARP created to be an abbreviated form of the Intervention Rating Profile (Witt & Elliott, 1985). The AARP (Tarnowski & Simonian, 1992) was developed as an eight-item measure that is rated on a 6-point Likert scale ranging from one (strongly disagree) to six (strongly agree). Higher scores represent higher acceptability of the intervention. The AARP has a Cronbach's alpha of .97 (Tarnowski & Simonian, 1992).
Measure: Acceptability of the intervention as measured by the number of participants who find an intervention to be acceptable at visit 3 Time: Following the intervention to visit 3, approx. 1 month from the interventionDescription: Acceptability will be measured by the AARP (Abbreviated Acceptability Rating Profile) questionnaire. AARP created to be an abbreviated form of the Intervention Rating Profile (Witt & Elliott, 1985). The AARP (Tarnowski & Simonian, 1992) was developed as an eight-item measure that is rated on a 6-point Likert scale ranging from one (strongly disagree) to six (strongly agree). Higher scores represent higher acceptability of the intervention. The AARP has a Cronbach's alpha of .97 (Tarnowski & Simonian, 1992).
Measure: Acceptability of the intervention as measured by the number of participants who find an intervention to be acceptable at visit 4 Time: Following the intervention to visit 4, approx. 4 months from the interventionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports